期刊文献+

miR-203在前列腺癌中的表达及其与预后的相关性 被引量:3

Expression of miR-203 in prostate carcinoma and its correlation with prognosis
原文传递
导出
摘要 目的探讨miR-203在前列腺癌组织中的表达及其与前列腺癌临床病理特征和患者预后的关系。方法应用实时荧光定量反转录PCR检测30例前列腺癌和10例前列腺良性增生组织中miR-203的表达,应用Kaplan—Meier生存曲线分析miR-203与患者预后的关系,多变量Cox比例风险回归模型筛选影响患者生存的独立预后因素。结果miR-203在前列腺癌组织中表达较良性增生组织增高,差异有统计学意义(P〈0.05),Gleason积分〉7分者较〈7分者miR-203表达量增高了约2倍;Gleason积分7~8分与前列腺良性增生症、Gleason积分9~10分与前列腺良性增生症、Gleason积分7~8分与7分、Gleason积分9~10分与〈7分的组间比较,miR-203的表达量分别增高了2.8、3.1、2.7、2.9倍,差异均有统计学意义(均P〈0.05)。miR-203表达与Gleason积分、临床分期及发生骨转移相关,miR-203高表达的患者生存时问明显缩短(P〈0.05)。结论miR一203表达异常可能在前列腺癌的发生、发展中发挥了一定作用,其表达水平与肿瘤恶性分化及患者不良预后密切相关,可作为提示肿瘤恶性程度和风险评估的分子标志物。 Objective To explore the expression of miR-203 in prostate carcinoma (PCa) and its correlation with clinicopathological factors and the patients" prognosis. Methods The expression of miR-203 in 30 cases of PCa and 10 cases of benign prostatic hyperplasia (BPH) were detected by using real-time PCR. Kaplan-Meier and multivariate Cox proportional hazards regression model analysis were applied to compare the survival curves and screen the independent prognosis factors respectively. Results Between the PCa and BPH tissues, there were significant differences in the expression of miR-203 (P 〈 0.05). With Gleason score getting higher, the levels of miR-203 expression were up-regulated gradually 2 times. Gleason grading 〉 7 scores vs BPH, Gleasen grading 9-10 scores vs BPH, Gleason grading 7-8 scores vs 7 scores, Gleason grading 9-10 scores vs 〈 7 scores, the levels of miR-203 expression were up-regulated 2.8, 3.1, 2.7, 2.9 times (all P 〈 0.05). Moreover, this elevation correlated with Gleason grading, clinical staging and bone metastasis. Furthermore, the survival time was decreased in patients with higher expression levels of miR-203 (P 〈 0.05). Conclusion Aberrant miRNA expression is partially associated with enhanced malignant degrees and poor prognosis in prostate tumorigenesis. The marker could be applied to indicate the malignant degrees and evaluate the patients' prognosis.
出处 《肿瘤研究与临床》 CAS 2013年第6期400-402,405,共4页 Cancer Research and Clinic
基金 山西省高等学校科技创新项目(20091170)
关键词 前列腺肿瘤 聚合酶链反应 预后 miR-203 Prostatic neoplasms Polymerase chain reaction Prognosis miR-203
  • 相关文献

参考文献13

  • 1Blenkiron C, Miska EA. miRNAs in cancer: approaches, aetiology,diagnostics and therapy. Hum Mol Genet, 2007,16: R106-113.
  • 2Zhang W, Dahlberg JE, Tam W. MioroRNAs in tumorigenesis: aprimer. Am J Pathol, 2007, 171: 728-738.
  • 3Yang K, Handorean AM, Iczkowski KA. MioroRNAs 373 and 520care downregulated in prostate cancer, suppress CD44 translation andenhance invasion of prostate cancer cells in vitro. Int J Clin ExpPathol, 2009,2:361-369.
  • 4Vitir,nhi& G, Lena AM, Latina A, et al. MiR-203 controls proliferation,migration and invasive potential of prostate cancer cell lines. CellCycle, 2011, 10: 1121-1131.
  • 5夏加增(综述).微小RNA与肿瘤转移[J].肿瘤研究与临床,2009,21(1):65-67. 被引量:7
  • 6Porkka KP, Pfeiffer MJ, Waltering KK, et al. MioroRNA expressionprofiling in prostate cancer. Cancer Res, 2007, 67: 6130-6135.
  • 7Livak KJ, Schmittgen TD. Analysis of relative gene expression datausing real-time quantitative PCR and the 2(-Delta Delta C(T)) method.Methods, 2001, 25: 402-408.
  • 8Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis showsthat some mioroRNAs rlownregulate large numbers of target mRNAs.Nature, 2005, 433: 769-773.
  • 9Blenkiron C, Miska EA. miRNAs in cancer: approaches, aetiology,diagnostics and therapy. Hum Mol Genet, 2007, 16: R106-113.
  • 10Esquela-Kerscher A, Slack FJ. Oncomirs -microRNAs with a role incancer. Nat Rev Cancer, 2006,6: 259-269.

二级参考文献26

  • 1Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl. J Med, 2005, 353: 1793-1801.
  • 2Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting bcl-2. Proc Natl Acad Sci U S A, 2005; 102: 13944-13949.
  • 3Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell, 2005, 120: 635-647.
  • 4Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res, 2004, 64: 3753- 3756.
  • 5Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull, 2006, 29: 903-906.
  • 6Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep, 2006, 16: 845-850.
  • 7Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 2005, 65: 7065- 7070.
  • 8O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Mye-regulated microRNAs modulate E2F1 expression. Nature, 2005, 435: 839-843.
  • 9He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature, 2005, 435: 828-833.
  • 10Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol, 2007, 27: 1859-1867.

共引文献6

同被引文献19

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部